Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-15,000
Closed -$3.07M 449
2022
Q1
$3.16M Buy
15,000
+8,500
+131% +$1.85M 0.09% 211
2021
Q4
$1.56M Sell
6,500
-5,000
-43% -$1.29M 0.03% 385
2021
Q3
$3.25M Buy
+11,500
New +$3.77M 0.1% 204
2021
Q2
Sell
-31,330
Closed -$9.49M 1034
2021
Q1
$8.77M Buy
31,330
+22,030
+237% +$5.94M 0.22% 104
2020
Q4
$2.28M Buy
+9,300
New +$2.4M 0.04% 355

Other funds holding BIIB

SG3 Management's BIIB Position: Q2 2022 in Review

SG3 Management sold out of Biogen (BIIB) in Q2 2022, closing a stake of 15,000 shares — an estimated $3.07M sold.

SG3 Management first reported a position in BIIB in Q4 2020 and held it in 5 quarters. The position peaked at $8.77M in Q1 2021. 928 funds tracked by Wall St. Rank hold BIIB as of Q2 2022.

  • SG3 Management reported no remaining Biogen position as of Q2 2022 after selling out during the quarter.
  • SG3 Management sold 15,000 Biogen shares in Q2 2022, an estimated $3.07M.
  • SG3 Management first reported a position in Biogen in Q4 2020 and held it in 5 quarters.
  • SG3 Management's Biogen position peaked at $8.77M in Q1 2021.
  • 928 funds tracked by Wall St. Rank held Biogen as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.